[The yield of tigecycline in the treatment of community-acquired pneumonia]

Abstract

Tigecycline is a novel antibiotic and it is the first glycylcycline of the tetracycline antibiotic class. It exhibits potent in vitro activity against causative pathogens that are most frequently isolated in patients with community-acquired pneumonia. The objective of this study is to review the literature about the efficacy of tigecycline in community-acquired pneumonia. Two randomized clinical studies showed tigecycline was not inferior when compared with levofloxacin for the treatment of patients with bacterial community-acquired pneumonia requiring hospitalization. Tigecycline was generally well tolerated in patients with community-acquired pneumonia. Major adverse effects were primarily gastrointestinal in nature. Tigecycline offers an antibiotic option that can be used in hospitalized patients with mild to moderate community-acquired pneumonia.